5-(iodoacetamido)fluorescein

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5-(iodoacetamido)fluorescein
• 英文别名: 4(5)-(Iodoacetamido)fluorescein；2-(3-hydroxy-6-oxoxanthen-9-yl)-4-[(2-iodoacetyl)amino]benzoic acid
• 化学式: C₂₂H₁₄INO₆
• 分子量: 515.261
• InChiKey: NQLYNFNRQHVPET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Bax channel blocker 、 5-(iodoacetamido)fluorescein 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以47%的产率得到(+/-)-4-[({-[3-(3,6-dibromocarbazol-9-yl)-2-hydroxypropyl]piperazin-1-yl}acetyl)amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid
  参考文献：
  名称：

  3,6-Dibromocarbazole Piperazine Derivatives of 2-Propanol as First Inhibitors of Cytochrome c Release via Bax Channel Modulation

  摘要：

  There is compelling evidence that Bax channel activity stimulates cytochrome c release leading ultimately to cell death, which is a key event in ischemic injuries and neurodegenerative diseases. Here 3,6-dibromocarbazole piperazine derivatives of 2-propanol are described as the first small and potent modulators of the cytochrome c release triggered by Bid-induced Bax activation in a mitochondrial assay. Furthermore, a mechanism of action is proposed, and fluorescent derivatives allowing the localization of such inhibitors are reported.

  DOI：

  10.1021/jm034107j

文献信息

• Protein Kinase Inhibitors and Methods for Identiying Same
  申请人：Lawrence S. David

  公开号：US20070254312A1

  公开（公告）日：2007-11-01

  Inhibitors of protein kinase C (PKC)α, PKCδ and PKCζ are provided which are selective for those PKC isotypes. Combinatorial libraries for identifying protein kinases are also provided, as are methods of identifying protein kinases using those libraries. Additionally, methods of treating a mammal having a deleterious condition, where the condition is dependent on a protein kinase for induction or severity, are provided. Methods of inhibiting protein kinases are also provided.

  提供了特异性作用于蛋白激酶C（PKC）α、PKCδ和PKCζ的抑制剂，以及用于识别蛋白激酶的组合化学文库，以及利用这些文库识别蛋白激酶的方法。此外，还提供了用于治疗患有依赖蛋白激酶诱导或严重性的有害状况的哺乳动物的方法。同时还提供了抑制蛋白激酶的方法。
• Substrates for beta-lactamase and uses thereof
  申请人：Tsien Y. Roger

  公开号：US20070184513A1

  公开（公告）日：2007-08-09

  Substrates for β-lactamase of the general formula I in which one of X and Y is a fluorescent donor moiety and the other is a quencher (which may or may not re-emit); R′ is selected from the group consisting of H, lower (i.e., alkyl of 1 to about 5 carbon atoms) and (CH 2 ) n OH, in which n is 0 or an integer from 1 to 5; R″ is selected from the group consisting of H, physiologically acceptable metal and ammonium cations, CHR 2 OCO(CH 2 ) n CH 3 , —CHR 2 OCOC (CH 3 ) 3 , acylthiomethyl, acyloxy-alpha -benzyl, delta-butyrolactonyl, methoxycarbonyloxymethyl, phenyl, methylsulphinylmethyl, beta-morpholinoethyl, dialkylaminoethyl, acyloxyalkyl, dialkylaminocarbonyloxymethyl and aliphatic, in which R 2 is selected from the group consisting of H and lower alkyl; A is selected from the group consisting of S, O, SO, SO 2 and CH 2 ; and Z′ and Z″ are linkers for the fluorescent donor and quencher moieties. Methods of assaying β-lactamase activity and monitoring expression in systems using β-lactamase as a reporter gene also are disclosed.

  通式I的β-内酰胺酶底物，其中X和Y中的一个是荧光给体基团，另一个是猝灭剂（可以或不可以再发射）；R'从H，较低的（即1到约5个碳原子的烷基）和（CH2）nOH中选择，其中n为0或1到5的整数；R"从H，生理上可接受的金属和铵阳离子，CHR2OCO（CH2）nCH3，—CHR2OCOC（CH3）3，酰硫甲基，酰氧-α-苯甲基，δ-丁酰内酯，甲氧羰氧甲基，苯基，甲硫氧甲基，β-吗啡啉乙基，二烷基氨基乙基，酰氧烷基，二烷基氨基羰氧甲基和脂肪族中选择，其中R2从H和较低的烷基中选择；A从S，O，SO，SO2和CH2中选择；Z'和Z"是荧光给体和猝灭剂基团的连接器。还公开了评估β-内酰胺酶活性和使用β-内酰胺酶作为报告基因监测表达的方法。
• 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS
  申请人：HALAZY Serge

  公开号：US20120040933A1

  公开（公告）日：2012-02-16

  piperazine compounds for use as pharmaceutically active compounds and in pharmaceutical formulations that are useful for the treatment of disorders associated with apoptosis, including neurodegenerative disorders, diseases associated with polyglutamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders, renal hypoxia, hepatitis and AIDS, where the piperazine compounds are represented by formula (I) and the terms R 0 , R 1 , R 2 , R 3 , k, l, m, n, and X are defined herein:

  使用哌嗪化合物作为药物活性化合物和制药配方，可用于治疗与凋亡相关的疾病，包括神经退行性疾病、多谷氨酸链相关疾病、癫痫、缺血、不育症、心血管疾病、肾脏缺氧、肝炎和艾滋病等。其中，哌嗪化合物由公式（I）表示，其中R0，R1，R2，R3，k，l，m，n和X的定义如下：
• US8053436B1
  申请人：——

  公开号：US8053436B1

  公开（公告）日：2011-11-08
• US8071761B2
  申请人：——

  公开号：US8071761B2

  公开（公告）日：2011-12-06